DGAP-News: Raptor Pharmaceutical Corp. Announces Pricing of Public Offering of Common Stock

Raptor Pharmaceutical Corp.

08.09.2011 15:47
—————————————————————————

NOVATO, Calif., 2011-09-08 15:46 CEST (GLOBE NEWSWIRE) —
Raptor Pharmaceutical Corp. (–Raptor– or the –Company–) (Nasdaq:RPTP), today
announced the pricing of its previously announced underwritten public offering
of 10,000,000 shares of its common stock at a price to the public of $4.00 per
share. The net proceeds to the Company from this offering are expected to be
approximately $37,250,000, after deduction of underwriting discounts and other
estimated offering expenses payable by the Company. In addition, the Company
has granted the underwriters a 30-day option to purchase up to an additional
1,500,000 shares of common stock to cover over-allotments, if any. The offering
is expected to close on or about September 13, 2011, subject to the
satisfaction of customary closing conditions.

The Company expects to use the net proceeds from the offering to fund the
Company–s commercial and pre-commercial efforts, clinical and preclinical
development programs and other general corporate activities.

JMP Securities LLC is acting as the sole book-running manager for the offering,
and Canaccord Genuity Inc. and Cowen and Company are acting as co-lead managers
for the offering.

A shelf registration statement on Form S-3 relating to the public offering of
the shares of common stock described above was filed with the Securities and
Exchange Commission (–SEC–) and is effective. A preliminary prospectus
supplement relating to the offering has been filed with the SEC and a final
prospectus supplement relating to the offering will be filed with the SEC and
will be available on the SEC–s website at www.sec.gov. When available, copies
of the final prospectus supplement may also be obtained from the offices of JMP
Securities LLC, 600 Montgomery Street, 10th Floor, San Francisco, California
94111, Attention: Prospectus Department, (415) 835-8985.

This press release shall not constitute an offer to sell or the solicitation of
an offer to buy, nor shall there be any sale of these securities, in any state
or jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any such
state or jurisdiction.

About Raptor Pharmaceutical Corp.

Raptor Pharmaceutical Corp. (Nasdaq:RPTP) (–Raptor–) seeks to research,
produce, and deliver medicines that improve life for patients with severe, rare
disorders. Raptor currently has product candidates in clinical development
designed to potentially treat nephropathic cystinosis, Non-alcoholic
Steatohepatitis (–NASH–), Huntington–s Disease (–HD–), aldehyde dehydrogenase
deficiency (–ALDH2–), and thrombotic disorder.

Raptor–s preclinical programs are based upon bioengineered novel drug
candidates and drug-targeting platforms derived from the human
receptor-associated protein and related proteins that are designed to target
cancer, neurodegenerative disorders and infectious diseases.

For additional information, please visit www.raptorpharma.com.

The Raptor Pharmaceutical Corp. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=7180

Forward Looking Statements

This document contains forward-looking statements as that term is defined in
the Private Securities Litigation Reform Act of 1995. These statements relate
to future events or our future results of operation or future financial
performance, including, but not limited to the following statement: that Raptor
will be able to close the public offering of its Common Stock or that Raptor
will be able to successfully develop any of its product candidates. These
statements are only predictions and involve known and unknown risks,
uncertainties and other factors, which may cause the Company–s actual results
to be materially different from these forward-looking statements Raptor
cautions readers not to place undue reliance on any such forward-looking
statements, which speak only as of the date they were made. Certain of these
risks, uncertainties, and other factors are described in greater detail in the
Company–s filings from time to time with the Securities and Exchange Commission
(the –SEC–), which Raptor strongly urges you to read and consider, including:
Raptor–s annual report on Form 10-K filed with the SEC on November 22, 2010;
and Raptor–s quarterly report on Form 10-Q filed with the SEC on July 12, 2011;
all of which are available free of charge on the SEC–s website at
http://www.sec.gov. Subsequent written and oral forward-looking statements
attributable to Raptor or to persons acting on its behalf are expressly
qualified in their entirety by the cautionary statements set forth in Raptor–s
reports filed with the SEC. Raptor expressly disclaims any intent or obligation
to update any forward-looking statements.

CONTACT: Trout Group (investors)
Lauren Glaser
(646) 378-2972
lglaser@troutgroup.com

EVC Group (media)
Janine McCargo
(646) 688-0425
jmccargo@evcgroup.com
News Source: NASDAQ OMX

08.09.2011 Dissemination of a Corporate News, transmitted by DGAP –
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP–s Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

—————————————————————————

Language: English
Company: Raptor Pharmaceutical Corp.

United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US75382F1066
WKN:

End of Announcement DGAP News-Service

—————————————————————————

  raptor-pharmaceutical-corp-announces-pricing-of-public-offering-of-common-stock